CN

CN
Our Latest Updates on Science and Services

WuXi Discovery Services

Jan 2022

OncoWuXi Newsletter

Jan 2022

OncoWuXi Newsletter

Dec 2021

OncoWuXi Newsletter

Nov 2021

OncoWuXi Newsletter

Oct 2021

WuXi Discovery Services

Oct 2021

OncoWuXi Newsletter

Sep 2021

OncoWuXi Newsletter

August 2021

OncoWuXi Newsletter

July 2021

RSDpress

June 2021

OncoWuXi Newsletter

June 2021

OncoWuXi Newsletter

May 2021

RSDpress

April 2021

RSDpress

March 2021

OncoWuXi Newsletter

March 2021

OncoWuXi Newsletter

Feb 2021

RSDpress

Jan 2021

OncoWuXi Newsletter

Jan 2021

RSDpress

Dec 2020

OncoWuXi Newsletter

Dec 2020

OncoWuXi Newsletter

Nov 2020

RSDpress

Nov 2020

OncoWuXi Newsletter

Oct 2020

RSDpress

Oct 2020

RSDpress

Sep 2020

OncoWuXi Newsletter

Sep 2020

OncoWuXi Newsletter

Aug 2020

RSDpress

Aug 2020

RSDpress

July 2020

OncoWuXi Newsletter

July 2020

OncoWuXi Newsletter

June 2020

OncoWuXi Newsletter

May 2020

RSDpress

May 2020

OncoWuXi Newsletter

April 2020

RSDpress

March 2020

OncoWuXi Newsletter

March 2020

OncoWuXi Newsletter

February 2020

OncoWuXi Newsletter

January 2020

OncoWuXi Newsletter

December 2019

OncoWuXi Newsletter

November 2019

Biology Newsletter

November 2019

OncoWuXi Newsletter

October 2019

OncoWuXi Newsletter

September 2019

OncoWuXi Newsletter

August 2019

Biology Newsletter

3D in vitro Assay Platform

RSDpress

July 2019

RSDpress

May 2020

OncoWuXi Newsletter

April 2020

RSDpress

March 2020

Explore More
OncoWuXi Newsletter
Jan 2022: WuXi AppTec ADC-related platform for preclinical research and drug-resistant tumor models Dec 2021: Special New Year Edition Nov 2021: WuXi AppTec humanized MC38 models, CT26 KRAS-G12C model and 10X visium spatial transcriptomics platform Oct 2021: WuXi AppTec genetically engineered cell lines for JAK and in-cell western for PROTAC screening Sep 2021: WuXi AppTec cancer vaccine discovery platform, Siglec-15 KO mouse model and NanoString platform Aug 2021: WuXi AppTec immune profiling in drug discovery and CLDN18.2-related tumor models. July 2021: ADC-related preclinical research platform and Capmatinib-resistant Hs 746T model . June 2021: Entrectinib-induced resistant CDX and PDX models and WuXi AppTec tumor metastasis models May 2021: WuXi AppTec CD47-related pathology service, Ibrutinib-resistant tumor model and radiation platform March 2021: CD73-related in vitro assays and CDK4/6, FGFR, or EGFR exon 20ins in vivo models Feb 2021: Palbociclib-induced Resistant Model of MCF-7 Jan 2021: Single Cell RNA Sequencing Service Dec 2020: Special New Year Edition Nov 2020: FLT3, RET, and RAF-MEK1/2 related tumor models. Oct 2020: Pharmacodynamics service platform. Sep 2020: FACS platform Aug 2020: NanoString platform for research and translational applications July 2020: Genetically engineered Ba/F3 cell lines June 2020: KRAS G12C related in vivo tumor models May 2020: Comprehensive pathology service platform Apr 2020: Drug resistant tumor models March 2020: EGFR related in vivo models Feb 2020: Genetically engineered Ba/F3 cell lines and corresponding in vivo/in vitro validation data Jan 2020: Immune checkpoint knockin humanized mouse tumor models and immune avatar humanized mouse tumor models Dec 2019: Special New Year Edition Nov 2019: Newly developed Luminex multiplex system Oct 2019: Newly developed in vitro angiogenesis assay Sep 2019: STING related assays and updates on KRAS relevant models Aug 2019: Genetically engineered Ba/F3 cell lines and corresponding in vivo/in vitro validation data July 2019:  in vivo efficacy platform for bispecific antibodies June 2019: integrated target identification and validation platform March 2019: nanostring platform for research and translational applications February 2019: immune checkpoint humanized knockin mouse tumor models 2019 Special New Year Edition
Biology Newsletter
Quantitative Histopathology of Fibrosis in an Animal Modal of NASH 3D in vitro Assay Platform Non-alcoholic steatohepatitis (NASH) pharmacology platform Chronic kidney disease (CKD) in vivo pharmacology services Myocardial infarction/heart failure (MI/HF) model in the large animals Nav1.8 - a target analgesic candidates validated by Phase 2 clinical study In vitro early toxicity testing service In vivo anti-hypertension service End-to-end platform supporting HBV drug discovery In vivo pharmacology on IBS/IBD animal models
WuXi Discovery Services
WuXi Discovery Services Jan 2022 WuXi Discovery Services Oct 2021 RSDpress June 2021 RSDpress April 2021 RSDpress March 2021 RSDpress Jan 2021 RSDpress Dec 2020 RSDpress Nov 2020 RSDpress Oct 2020 RSDpress Sep 2020 RSDpress Aug 2020 RSDpress July 2020 RSDpress May 2020 RSDpress March 2020 RSDpress March 2019 RSDpress December 2018 RSDpress July 2018 RSDpress May 2018 RSDpress February 2018 RSDpress November 2017 RSDpress August 2017 RSDpress March 2017